Table 1.
Baseline demographical and clinical features of the Peruvian HCC patients.
| Feature | Mean value or percent (±s.d.) | Range or proportion |
|---|---|---|
| Demography | ||
| Age (years) | 41.6 ± 2.6 | [6–81] |
| Sex-ratio (M:F) | 1.5 | 39:26 |
| Birthplace in southern central Andes | 33.8% | 22/65 |
| Viral serology | ||
| HBsAg(+) | 50.7% | 33/65 |
| Anti-HBc(+) total | 72.3% | 47/65 |
| Anti-HDV(+) | 1.5% | 1/65 |
| Anti-HCV(+) | 3% | 2/65 |
| Tumor features | ||
| Tumor size (cm-diameter) | 14.4 ± 0.7 | [5–30] |
| Number of liver segments involved | 3.5 ± 0.2 | [1–8] |
| Poorly differentiated | 21.5% | 14/65 |
| Multi-nodular | 27.6% | 18/65 |
| Liver features | ||
| Cirrhosis | 3% | 2/65 |
| Fibrosis | 9.2% | 6/65 |
| Inflammation | 26.1% | 17/65 |
| Steatosis | 12.3% | 8/65 |
| Dysplasia | 1.5% | 1/65 |
| Healthy liver | 56.9 | 37/65 |
| Blood test | ||
| AFP (ng/mL) | 1.3E + 05 ± 2.8E + 04 | [1–8E + 05] |
| ALT (U/L) | 61.7 ± 8.9 | [8–330] |
| AST (U/L) | 103.9 ± 13.5 | [11–463] |
| ALP (U/L) | 309.2 ± 33.3 | [12–1,331] |
Footnote: Percentages are expressed as a ratio of the 65 patients investigated for the considered parameter. Mean values are presented with ±standard deviation (s.d.). AFP, alpha-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, Aspartate aminotransferase; total Anti-HBc(+), antibody against hepatitis B core antigen; Anti-HCV, hepatitis C virus antibody; Anti-HDV, hepatitis D virus antibody.